Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

REM sleep and central monoamine oxidase inhibition

  • 36 Accesses

  • 54 Citations

Abstract

Our preliminary observations on the relationship of sleep and lumbar CSF acid monoamine metabolite levels suggested a greater decrease in lumbar CSF HVA as compared to 5HIAA following clinical doses of phenelzine in the presence of virtually total REM suppression. This report on nine psychiatric patients confirms these findings in a larger sample and thus supports an inhibitory role for dopamine or other catecholamines in REM sleep mechanisms. The drug-withdrawal results indicate that the four patients with REM rebound showed increases in HVA levels compared to treatment levels, while the single patient with no REM rebound also had no increase in HVA levels.

This is a preview of subscription content, log in to check access.

References

  1. Aghajanian, G. K., Graham, A. W., Sheard, M. H.: Serotonin-containing neurons in brain: depression of firing by monoamine oxidase inhibitors. Science 169, 1100–1102 (1970).

  2. Akindele, M. O., Evans, J. I., Oswalk, I.: Monoamine oxidase inhibitors, sleep, and mood. Electroenceph. clin. Neurophysiol. 29, 47–56 (1970).

  3. Ashcroft, G. W., Crawford, T. B. B., Dow, R. C., Moir, A. T. B.: Release of amine metabolite into ventricular perfusion fluid as an index of turnover. In: Metabolism of amines in the brain. G. Hooper London: Macmillian 1969.

  4. Bevan Jones, A. B., Pare, C. M. B., Nicholson, W. J., Price, K., Stacey, R. S.: Brain amine concentrations after monoamine oxidase inhibitor administration. Brit. med. J. 1972 I, 17–19.

  5. Bowers, M. B., Jr.: Clinical measurements of central dopamine 5-hydroxytryptamine metabolism. Neuropharmacology 11, 101–111 (1972a).

  6. Bowers, M. B., Jr.: Cerebrospinal fluid 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) following probenecid in unipolar depressives treated with amitriptyline. Psychopharmacologia (Berl.) 23, 26–33 (1972b).

  7. Bowers, M. B., Jr., Kupfer, D. J.: Central monoamine oxidase inhibition and REM sleep. Brain Res. 35, 561–564 (1971).

  8. Forn, J., Mailing, H. M., Gessa, G. L.: Homovanillic and 5-hydroxyindoleacetic acids in cerebrospinal fluid after probenecid: Measurement of brain monoamine oxidase inhibition in vivo. Proc. Soc. exp. Biol. (N.Y.) 133, 1310–1313 (1970).

  9. Hartmann, E., Chung, R., Draskoczy, P. R., Schildkraut, J. J.: Effects of 6-hydroxydopamine on sleep in the rat. Nature (Lond.) 233, 425–427 (1971).

  10. Himmelhoch, J. M., Detre, T. P., Kupfer, D. J., Swartzburg, M., Byck, R.: Treatment of previously-intractable depressions with tranylcypromine and lithium. J. nerv. ment. Dis. 155, 216–220 (1972).

  11. Jouvet, M.: Mechanisms of the states of sleep: A neuropharmacological approach. Res. Publ. Ass. nerv. ment. Dis. 45, 86–126 (1967).

  12. Klein, D. F., Davis, J. M.: Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins 1969.

  13. Kupfer, D. J., Foster, F. G.: Sleep and activity in a psychotic depression. J. nerv. ment Dis. (in press).

  14. Kupfer, D. J., Foster, F. G., Bowers, M. B., Jr.: Selective suppression of REM sleep by probenecid. Brain Res. 41, 205–210 (1972).

  15. Pare, C. M. M., Rees, L., Sainsbury, M. S.: Differences of two genetically specific types of depression by the response to antidepressants. Lancet 1962, 1340–1343.

  16. Rechtschaffen, A., Kales, A. A.: A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. Bethesda, Maryland: N.I.N.D.B. 1968.

  17. Van Praag, H. M., Korf, J.: Retarded depression and the dopamine metabolism. Psychopharmacologia (Berl.) 19, 199–203 (1971).

  18. Wyatt, R. J., Chase, T. N., Kupfer, D. J., Scott, J., Snyder, F., Sjoerdsma, A., Engelman, K.: Brain catecholamines and human sleep. Nature (Lond.) 233, 63–64 (1971).

  19. Wyatt, R. J., Fram, D. H., Kupfer, D. J., Snyder, F.: Total prolonged drug-induced REM sleep suppression in anxious-depressed patients. Arch. gen. Psychiat. 24, 145–155 (1971a).

Download references

Author information

Additional information

This investigation was supported in part by Research Scientist Development Award KO1 MH 70012 to D.J.K. and U.S.P.H.S. grant MH 12873. We wish to thank Angelica Rozitis, Amanda Smith, Philip Rogers and Richard McPartland for technical assistance and the nursing staff of the research unit, Connecticut Mental Health Center, whose invaluable and consistent help made this study possible.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kupfer, D.J., Bowers, M.B. REM sleep and central monoamine oxidase inhibition. Psychopharmacologia 27, 183–190 (1972). https://doi.org/10.1007/BF00422798

Download citation

Key words

  • Cerebrospinal Fluid
  • 5-Hydroxyindoleacetic Acid
  • Homovanillic Acid
  • Dopamine
  • Depression
  • REM Sleep
  • Phenelzine
  • Monoamine Oxidase Inhibition